Drug intelligence / Profile preview

fluorouracil + methotrexate + thiotepa + vinblastine

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

This is a combination chemotherapy regimen consisting of four anticancer drugs: fluorouracil (5-FU), methotrexate, thiotepa, and vinblastine. The combination has been used in the treatment of advanced breast cancer, particularly for patients who have failed prior systemic therapy. Each component has a different mechanism of action: fluorouracil is an antimetabolite that interferes with DNA and RNA synthesis, methotrexate inhibits dihydrofolate reductase, thiotepa is an alkylating agent, and vinblastine is a vinca alkaloid that disrupts microtubule formation.

Targets

TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))DHFR (Dihydrofolate reductase)DNA

Beyond the preview

Go deeper on fluorouracil + methotrexate + thiotepa + vinblastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluorouracil + methotrexate + thiotepa + vinblastine.

Explore the full profile